Figure 4
Effect of CBL on neuropathological alterations in Tau/GSK3β bigenic mice. (A) Immunohistochemical analysis of dendritic pathology as evidenced by MAP2 immunoreactivity in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. Boxes in upper panels are represented at higher magnification in the lower panels. (B) Quantitative analysis of MAP2 immunoreactivity in the CA1 region of the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (C) Quantitative analysis of MAP2 immunoreactivity in the molecular layer (ML) of the dentate gyrus of the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (D) Immunohistochemical analysis neuronal density as evidenced by NeuN immunoreactivity in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. Boxes in upper panels are represented at higher magnification in the lower panels. (E) Quantitative analysis of NeuN immunoreactivity in the CA1 region of the hippocampus the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (F) Quantitative analysis of NeuN immunoreactivity in the molecular layer of the dentate gyrus of the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (A, D) Scale bar in upper panels = 250 μm, in lower panels = 50 μm. (B, C, E, F) Error bars represent mean ± SEM (n = 6 per group, 6 m/o). *Indicates a significant difference (p < 0.05) between vehicle and CBL treated Tau/GSK3β bigenic mice analyzed by one-way ANOVA and Dunnett’s post hoc test.